symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
APRE,5.33,0,47498,19916451,0,0.474-15.2,0.13,"Aprea Therapeutics, Inc.",USD,0001781983,US03836J1025,03836J102,NASDAQ Global Select,NASDAQ,Biotechnology,https://atrinpharma.com,"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.",Dr. Oren  Gilad Ph.D.,Healthcare,US,9,617-463-9385,535 Boylston St.,Boston,MA,02116,2.52046,3.61046,https://financialmodelingprep.com/image-stock/APRE.png,2019-10-03,True,False,True,False,False
